A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
This trial is designed to enroll postmenopausal patients with locally advanced or metastatic, HER2- and HR+ breast cancer not amenable to curative treatment by surgery or radiotherapy, and whose disease has progressed on or after prior endocrine therapy.
Patients must undergo molecular pre-screening prior to entry.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
La Jolla, California 92093-0658, United States
Tampa, Florida 33612, United States
Park Ridge, Illinois 60068-0736, United States
Livingston, New Jersey 07039, United States
Troy, New York 12180, United States
Greenville, South Carolina 29605, United States
San Antonio, Texas 78229, United States
Buenos Aires, Buenos Aires C1050AAK, Argentina
Rio Negro, Viedma 8500, Argentina
Saint-Herblain Cédex, 44805, France
Niaosong Township, Taiwan 83301, Taiwan